Anaplastic oligodendrogliomas: Prognostic factors for tumor recurrence and survival

Oncology

Volumn 65, Issue 3, 2003, Pages 259-266

  Puduvalli, Vinay K ^a,e   Hashmi, Masood ^a   McAllister, Leslie D ^b   Levin, Victor A ^a   Hess, Kenneth R ^a   Prados, Michael ^c   Jaeckle, Kurt A ^a   Yung, W K Alfred ^a   Buys, Saundra S ^d   Bruner, Janet M ^a   Townsend, Jeannette J ^d   Davis, Richard ^c   Sawaya, Raymond ^a   Kyritsis, Athanassios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UT MDACC   (United States)

Author keywords

Anaplastic oligodendroglioma; Brain neoplasms; Disease progression; Mortality; Prognosis

Indexed keywords

BROXURIDINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; FLUOROURACIL; HYDROXYUREA; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR RECURRENCE; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0344737846     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074479     Document Type: Article

References (24)

1. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH: Oligodendrogliomas: The Mayo Clinic experience. J Neurosurg 1992;76:428-434.
2. Couldwell WT, Hinton DR: Oligodendroglioma; in Kaye AH, Laws ER (eds): Brain Tumors. New York, Churchill Livingstone, 1995, pp 479-491.
3. Allison RR, Schulsinger A, Vongtama V, Barry T, Shin KH: Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys 1997;37:399-403.
4. Smith MT, Ludwig CL, Armbrustmacher VW, Henry JM, Earle KM: Histological characteristics and biological behavior of oligodendrogliomas. Trans Am Neurol Assoc 1980;105:35-37.
5. Bruner JM: Neuropathology of malignant gliomas. Semin Oncol 1994;21:126-138.
6. Wallner KE, Gonzales M, Sheline GE: Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 1988;68:684-688.
7. Winger MJ, Macdonald DR, Cairncross JG: Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989;71:487-493.
8. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360-364.
9. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold CJ: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12:2013-2021.
10. Kyritsis AP, Yung WK, Bruner J, Gleason MJ, Levin VA: The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993;32:365-370.
11. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479.
12. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW: Grading of oligodendrogliomas. Cancer 1983;52:2107-2114.
13. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol 1993;3:255-268.
14. Elashoff RM, Lee JJ, Afifi AA: A note on confidence limits for quartiles with right censored data. Stat Med 1989;8:1269-1276.
15. Levin VA, Maor MH, Thall PF, Yung WK, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L: Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1995;33:357-364.
16. Boiardi A, Silvani A, Pozzi A, Farinotti M, Fariselli L, Broggi G, Salmaggi A: Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy. J Neurooncol 1997;34:179-185.
17. Walker MD, Green SB, Byar DP, Alexander EJ, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MSJ, Mealey JJ, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KRJ, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitro-soureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-1329.
18. Nijjar TS, Simpson WJ, Gadalla T, McCartney M: Oligodendroglioma. The Princess Margaret Hospital experience (1958-1984). Cancer 1993;71:4002-4006.
19. Davis FG, Freels S, Grutsch J, Barlas S, Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998;88:1-10.
20. Shimizu KT, Tran LM, Mark RJ, Selch MT: Management of oligodendrogliomas. Radiology 1993;186:569-572.
21. Lindegaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T, Dahl O, Ganz J: Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 1987;67:224-230.
22. Kim L, Hochberg FH, Thornton AF, Harsh GR, Patel H, Finkelstein D, Louis DN: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996;85:602-607.
23. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG: Salvage chemotherapy for oligodendroglioma. J Neurosurg 1996;85:597-601.
24. Jenkins RB, Curran W, Scott CB, Cairncross G: Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am J Clin Oncol 2001;24:506-508.